摘要
二甲双胍作为最经典的治疗糖尿病的药物之一,近期因其潜在的抗肿瘤作用再次引起人们的广泛关注。研究发现二甲双胍不仅可以降低糖尿病人群多种肿瘤的发病率,同时还可以延长肿瘤患者的生存期,跟进的大量基础研究也证实了二甲双胍的抗肿瘤活性。在消化系统肿瘤方面,虽然多数回顾性流行病学研究发现二甲双胍对多种肿瘤患者有较好的保护作用,但仍有争议。目前的抗肿瘤依据主要源于回顾性病例对照研究,在前瞻性临床研究方面部分观察到积极的治疗作用,但具体二甲双胍的使用对哪种消化系统肿瘤的保护最为有力、多大剂量能发挥保护作用和患者的耐受性如何等仍处于临床探索阶段。文章将从抗肿瘤机制、回顾性流行病学证据和前瞻性临床研究方面,阐述二甲双胍对消化系统肿瘤的治疗作用。
Metformin is one of the most classic anti-diabetes medications. Recently, it’s grabbing much attention as a potential anti-tumor treatment. Metformin has been shown to reduce the risk of various types of cancer and cancer mortality in patients with diabetes mellitus. Subsequently, preclinical studies have confirmed its anti-tumor activity. As for digestive system tumors, most retrospective epidemiological studies concluded that Metformin has good protective effect on different types of cancer, but there are still some controversial sounds. Anti-cancer activity of Metformin was based primarily on retrospective case control studies and some prospective studies certified its promising effectiveness, but which type of digestive system tumors is best suited, how big a dose will be needed to be effective and will it be well tolerated still in clinical research. This article will elaborate anti-tumor properties of Metformin from anti-tumor mechanism, retrospective epidemiological evidence and prospective clinical studies.
作者
高先春
潘亚楠
潘妍
施育鹏
聂勇战
GAO Xian-chun;PAN Ya-nan;PAN Yan;SHI Yu-peng;NIE Yong-zhan(State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an710032, China;School of Life Science, Northwest University, Xi'an 710032, China)
出处
《肿瘤综合治疗电子杂志》
2019年第2期34-39,共6页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
国家重点研发计划(2016YFC1303200)
关键词
消化系统肿瘤
二甲双胍
糖尿病
预后
Gastrointestinal cancer
Metformin
Diabetes
Prognosis
